MMS Insights
webinar
April 30th, 2025
Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies
webinar
March 25th, 2025
Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success
news
March 19th, 2025
MMS REMS-focused Technology bolsters Full-Service REMS Solutions
perspectives
March 6th, 2025
Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products
perspectives
February 13th, 2025
Helping European Drug Development Companies Succeed in the US Market
news
February 12th, 2025
MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO
perspectives
January 30th, 2025
Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned
perspectives
January 21st, 2025
REMS Modifications and Revisions: A Retrospective from the Past 12 Months
regulatory intelligence
January 17th, 2025
The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development
regulatory intelligence
January 17th, 2025
New FDA Protocol Deviation Guidance: Planning for the Things That Don’t Go According to Plan
perspectives
January 9th, 2025
How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA
perspectives
January 2nd, 2025
Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations